Trimipramine and duodenal ulcer.

The gastric acid secretion, fasting serum gastrin and serum concentration of trimipramine were studied in 20 patients with duodenal ulcer during a 6 weeks treatment with trimipramine. Ulcer healing was examined endoscopically. In the group of 11 patients with healed ulcers the gastric acid secretion decreased significantly at 3 and 6 weeks in contrast to the 9 patients in whom ulcers did not heal, indicating a different antisecretory response in the two groups. The serum concentration of trimipramine was similar in both groups during treatment. Possible mechanisms of action of trimipramine in peptic ulcer disease and problems concerning clinical response and dose are discussed.